TNON — Tenon Medical, Inc.

Summary of Tenon Medical (TNON) Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 Revenue: $1.5 million, a 92% increase from $0.8 million in Q4 2024.
• Full Year Revenue: $3.9 million, a 20% increase from $3.3 million in 2024.
• Gross Profit: $1 million (69% of revenue) in Q4 2025, up from $0.4 million (46% of revenue) in Q4 2024.
• Annual Gross Profit: $2.4 million (60% of revenue) for 2025, compared to $1.7 million (52% of revenue) in 2024.
• Operating Expenses: $3.9 million in Q4 2025, up from $3.5 million in Q4 2024; total operating expenses for 2025 were $15.2 million, down from $15.5 million in 2024.
• Net Loss: $2.8 million ($0.29 per share) in Q4 2025, improved from a net loss of $3.1 million ($0.98 per share) in Q4 2024; total net loss for 2025 was $12.6 million ($1.70 per share), down from $13.7 million in 2024.
• Cash Position: $3.8 million in cash and equivalents at year-end, down from $6.5 million in 2024.

2. Strategic Updates and Business Highlights

• Product Development: Received FDA 510(k) clearance for the next-generation SImmetry+ SI-Joint Fusion System, expanding the product portfolio and enhancing market competitiveness.
• Clinical Engagement: Conducted 24 physician training sessions in Q4 to support the adoption of new technologies.
• Financial Flexibility: Completed a $2.85 million PIPE financing and a $4.3 million private placement of senior convertible notes to fund commercial expansion and product launches.
• Intellectual Property: Expanded patent portfolio with notices of allowance for multiple applications expected to issue in 2026.

3. Forward Guidance and Outlook

• 2026 Expectations: Management expressed optimism about revenue growth driven by increased adoption of SImmetry+ and other products. They anticipate continued momentum from the strong performance in the latter half of 2025.
• Operational Efficiency: Plans to optimize cost structure and scale operations to enhance market reach.
• Market Positioning: Focus on leveraging a multi-product portfolio to address diverse physician preferences and patient needs.

4. Bad News, Challenges, or Points of Concern

• Cash Decrease: Notable decline in cash reserves from the previous year, which could impact operational flexibility if not managed effectively.
• Net Loss: Despite improvements, the company continues to report significant net losses, which may raise concerns about long-term sustainability and profitability.
• Market Competition: As Tenon expands its product offerings, it may face increased competition in the medical device sector, particularly in the SI-joint fusion market.

5. Notable Q&A Insights

• Operating Expense Baseline: Management indicated that Q4 2025's operating expenses of $3.9 million could serve as a baseline for 2026, with expectations of maintaining a disciplined cost structure.
• Revenue Growth Drivers: The company is optimistic about sustaining revenue growth through the commercialization of SImmetry+ and other pipeline products, with a focus on expanding physician engagement.
• Physician Adoption: The introduction of a multi-solution portfolio has opened new opportunities for access to physicians and medical centers, enhancing the company's market presence.

Overall, Tenon Medical reported strong growth in Q4 2025, driven by increased revenue and operational efficiencies, while also positioning itself for future expansion through strategic product launches and financial maneuvers. However, challenges remain in terms of cash reserves and ongoing net losses.